Recent news and predictions for venture capital have been anything but cheery. With a wobbly economy and uncertainty surrounding government reforms, investors are understandably cautious. Entrepreneur Magazine even goes so far as to ask whether venture...

At Safeguard Scientifics, we offer our partner companies quality resources to promote their growth and help them recruit strong management teams for their future. We currently have 16 partner companies, and we strive to provide each of them with operational...

The past 12 months have exciting at Safeguard Scientifics. In December of 2010, partner companies Clarient and Avid Radiopharmaceuticals were both acquired by giants in the life sciences industry. Safeguard experienced the largest cash return in our 58-year...

Here at Safeguard Scientifics, we provide capital to growth-stage companies in both the life sciences and technology. It’s important to note, however, that Safeguard provides a lot more than just capital to our partner companies. Whether it is helping...

Last week our own Gary J. Kurtzman, MD, Senior Vice President and Managing Director in the Safeguard Life Sciences Group, participated on a panel at the Southeast BIO Investor Forum in North Carolina that featured “The Story of Shire’s Acquisition...

The IPO Task Force unveiled a new effort to ease the IPO road for emerging companies in its report, “Rebuilding the IPO On-Ramp.” The report calls for an easing of regulations that it says are holding back emerging U.S. companies. Among its recommendations,...